ReviewRNA (New York, N.Y.)2009
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.
Review in RNA (New York, N.Y.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis.International journal of molecular sciences · 2023Pooled it
- Pooled it
- miR-17 ~ 92 suppresses proliferation and invasion of cervical cancer cells by inhibiting cell cycle regulator Cdt2.Discover oncology · 2023Article
- miR-34a negatively regulates cell cycle factor Cdt2/DTL in HPV infected cervical cancer cells.BMC cancer · 2022Article
- Regulatory Role of microRNAs Targeting the Transcription Co-Factor ZNF521 in Normal Tissues and Cancers.International journal of molecular sciences · 2021Review
- Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer.The Journal of biological chemistry · 2020Article
- Differently expressed microRNA in response to the first Ig replacement therapy in common variable immunodeficiency patients.Scientific reports · 2020Article
- miR-34b-3p protects against acute kidney injury in sepsis mice via targeting ubiquitin-like protein 4A.The Kaohsiung journal of medical sciences · 2020Article
- miR-183-3p suppresses proliferation and migration of keratinocyte in psoriasis by inhibiting GAB1.Hereditas · 2020Article
- PBMC gene expression profiles of female Bangladeshi adults chronically exposed to arsenic-contaminated drinking water.Environmental pollution (Barking, Essex : 1987) · 2020Article
- The activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis.American journal of translational research · 2020Article
- Deregulation of SATB2 in carcinogenesis with emphasis on miRNA-mediated control.Carcinogenesis · 2019Review
- Expression profile of microRNAs in porcine alveolar macrophages after Toxoplasma gondii infection.Parasites & vectors · 2019Article
- Modeling the Dynamics of Let-7-Coupled Gene Regulatory Networks Linking Cell Proliferation to Malignant Transformation.Frontiers in physiology · 2019Article
- Relation ofCancer cell international · 2019Article
- MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in papillary thyroid carcinoma.Saudi journal of biological sciences · 2018Article
- MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.PloS one · 2017Article
- Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma.OncoTargets and therapy · 2017Article
- KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.Molecular oncology · 2016Article
- Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer.International journal of molecular sciences · 2016Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformation of normal cells into malignant tumors requires the acquisition of six hallmark traits, e.g., self-sufficiency in growth signals, insensitivity to antigrowth signals and self-renewal, evasion of apoptosis, limitless replication potential, angiogenesis, invasion, and metastasis, which are common to all cancers (Hanahan and Weinberg 2000). These new cellular traits evolve from defects in major regulatory microcircuits that are fundamental for normal homeostasis. The discovery of microRNAs (miRNAs) as a new class of small non-protein-coding RNAs that control gene expression post-transcriptionally by binding to various mRNA targets suggests that these tiny RNA molecules likely act as molecular switches in the extensive regulatory web that involves thousands of transcripts. Most importantly, accumulating evidence suggests that numerous microRNAs are aberrantly expressed in human cancers. In this review, we discuss the emergent roles of microRNAs as switches that function to turn on/off known cellular microcircuits. We outline recent compelling evidence that deregulated microRNA-mediated control of cellular microcircuits cooperates with other well-established regulatory mechanisms to confer the hallmark traits of the cancer cell. Furthermore, these exciting insights into aberrant microRNA control in cancer-associated circuits may be exploited for cancer therapies that will target deregulated miRNA switches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.